Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib with pre-operative radiotherapy for soft tissue sarcoma
ACTRN12608000474358Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in soft tissue sarcoma (STS) (3 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Maximum tolerated dose and safety/tolerability of sunitinib with pre-operative radiotherapy. Started Sep 2008; status: recruiting.
02
Drugs
sunitinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ACTRN12608000474358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000474358.